Printer Friendly

BIOGEN, INC. FILES PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK

BIOGEN, INC. FILES PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK
 CAMBRIDGE, Mass., Nov. 1 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) filed today with the U.S. Securities and Exchange Commission a registration statement for a public offering of 2 million shares of common stock and an over-allotment option for an additional 300,000 shares. All of such shares are being offered by the company.
 The offering is being managed by Lehman Brothers, Hambrecht & Quist Incorporated and Merrill Lynch and Co.
 Together with the company's existing cash and short-term investments, these funds will be used for general corporate purposes, including research, development, manufacturing and the commercialization of products.
 Biogen, Inc., headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human health care through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon, hepatitis vaccines and hepatitis diagnostic products. Biogen is focused primarily on developing and testing products used for the treatment of cardiovasscular disease, inflammatory diseases, AIDS and certain cancers.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under securities laws of any such state.
 -0- 11/1/91
 /CONTACT: John W. Catterall of Biogen, Inc., 617-252-9897/
 (BGEN) CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: OFR KM-DH -- NE007 -- 0285 11/01/91 14:11 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1991
Words:304
Previous Article:INITIAL PUBLIC OFFERING OF 3 MILLION SHARES OF ALTEON COMMON STOCK AT $15 PER SHARE
Next Article:INTERNATIONAL TOTALIZATOR SYSTEMS REPORTS THIRD QUARTER RESULTS
Topics:


Related Articles
BIOGEN REPORTS SECOND QUARTER 1993 EARNINGS OF $5.6 MILLION VS. $0.7 MILLION IN SECOND QUARTER 1992
Biogen Announces 2-For-1 Stock Split
Biogen Announces That Board Of Directors Authorizes Repurchase Of Up To 2,500,000 Shares Of Common Stock
Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader.
Biogen Idec Reports Fourth Quarter Earnings per Share of $0.24 (Adjusted Pro Forma); Full Year 2003 Earnings per Share of $1.22 (Adjusted Pro Forma);...
Biogen Idec Reports Third Quarter 2004 Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters